Invesco Ltd. Invests $32.70 Million in Cellebrite DI Ltd. (NASDAQ:CLBT)

Invesco Ltd. bought a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,484,322 shares of the company's stock, valued at approximately $32,700,000. Invesco Ltd. owned approximately 0.72% of Cellebrite DI as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp grew its holdings in shares of Cellebrite DI by 7.3% in the third quarter. State Street Corp now owns 443,700 shares of the company's stock valued at $7,472,000 after purchasing an additional 30,052 shares during the period. Barclays PLC grew its stake in shares of Cellebrite DI by 29.1% in the 3rd quarter. Barclays PLC now owns 263,657 shares of the company's stock valued at $4,439,000 after buying an additional 59,395 shares during the period. Tidal Investments LLC grew its stake in shares of Cellebrite DI by 59.3% in the 3rd quarter. Tidal Investments LLC now owns 104,478 shares of the company's stock valued at $1,759,000 after buying an additional 38,887 shares during the period. Lord Abbett & CO. LLC acquired a new stake in shares of Cellebrite DI during the 3rd quarter worth approximately $11,523,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Cellebrite DI during the 3rd quarter valued at approximately $23,402,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on CLBT shares. JPMorgan Chase & Co. raised their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Lake Street Capital upped their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $23.43.

Cellebrite DI Stock Up 6.1 %

NASDAQ:CLBT traded up $1.12 on Wednesday, reaching $19.51. 230,079 shares of the company's stock were exchanged, compared to its average volume of 1,404,980. The firm has a market capitalization of $4.67 billion, a price-to-earnings ratio of -14.04, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The business has a fifty day moving average of $18.79 and a 200-day moving average of $20.10.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, equities analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.